PharmaPoint: Alzheimer's Disease Global Drug Forecast and Market Analysis to 2023 - Event Driven update
Single User License - $10995 Site User License - $21990 Corporate User License - $32985 Publication Date - May 2015 Pages - 409 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary • Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation either by a home care professional or family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL), both for the patients and their caretakers. With rapidly accelerating worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made to develop a new treatment for AD, as current pharmacologic management is known to only provide temporary improvement of symptoms.
Contact: debora@reportstack.com Reportstack Market Research
Scope • Overview of AD and mild cognitive impairment (MCI), including etiology, general symptoms, country-specific compliance/caregiving data and epidemiology. • Annualized AD market revenue, annual cost of treatment and usage patterns from 2013 and forecast for ten years to 2023. • Key topics covered include strategic competitor assessment, unmet needs, clinical trial mapping and implications for the AD market. • Pipeline analysis: comprehensive data split across AD disease severities for disease-modifying and symptomatic therapies with novel mechanisms of action in AD, including Lilly’s solanezumab, Biogen’s aducanumab, Roche’s gantenerumab and crenezumab (Phase II). Merck & Co.’s M-8931, and Lilly/AstraZeneca’s AZD-3293. Contact: debora@reportstack.com Reportstack Market Research
Key Findings • Guidelines are not closely followed due to the heterogeneity of symptoms. • There is a widespread reluctance to seek treatment in the absence of curative therapies. • Diagnosis in early stages of the disease remains a challenge and will affect the growth of the market over the 2013-2023 forecast period. • Poor consensus over clinical trial endpoints required for approval. • Symptoms related to AD require better treatment options. • Amyloid beta is the focus of the late-stage pipeline. • Disease-modifying therapies such as passive immunotherapies and BACE inhibitors will revitalize the AD market.
Contact: debora@reportstack.com Reportstack Market Research
Companies Mentioned Actavis Lundbeck Eisai Pfizer Novartis Roche Eli Lilly Merck & Co. AstraZeneca Takeda Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research